Cholecystokinin-cholescintigraphy in adults: Consensus recommendations of an interdisciplinary panel

John K. Di Baise, Bryan K. Richmond, Harvey A. Ziessman, Gregory T. Everson, Robert D. Fanelli, Alan H. Maurer, Ann Ouyang, Peter Shamamian, Richard J. Simons, Laura A. Wall, Thomas J. Weida, Mark Tulchinsky

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background and aims: Cholecystokinin-cholescintigraphy (CCK-CS) provides a physiologic, noninvasive, and quantitative method for assessing gallbladder contraction and calculation of a gallbladder ejection fraction (GBEF). At present, it is used most commonly to identify patients with suspected functional gallbladder disorder. However, the methodology of CCK infusion and normal values differ markedly among imaging centers. Methods: This document represents the consensus opinion of an interdisciplinary panel that gathered to assess the current optimal method for performing CCK-CS in adults, potential uses and limitations of CCK-CS, and questions that require further investigation. Results: The panel recommended the use of a single, standardized, recently described CCK-CS protocol that involves infusion of 0.02 μg/kg of sincalide over 60 minutes with a normal GBEF defined as ≥38%. The panel emphasized the need for a large, multicenter, prospective clinical trial to establish the utility of CCK-CS in the diagnosis of functional gallbladder disease. Although not without controversy regarding its clinical utility, the primary indication for CCK-CS at present is the well-selected patient with suspected functional gallbladder disorder. Conclusion: Agreement was reached that the adoption of this standardized protocol is critical to improve how CCK-CS is used to direct patient care and will represent an improvement over the diverse methods currently in use by eliminating the current lack of uniformity and adding both reliability and credibility to the results.

Original languageEnglish (US)
Pages (from-to)63-70
Number of pages8
JournalClinical Nuclear Medicine
Volume37
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Cholecystokinin
Gallbladder
Gallbladder Diseases
Sincalide
Patient Care
Reference Values
Clinical Trials

Keywords

  • Cholecystokinincholescintigraphy
  • Functional gallbladder disorder
  • Gallbladder ejection fraction

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Di Baise, J. K., Richmond, B. K., Ziessman, H. A., Everson, G. T., Fanelli, R. D., Maurer, A. H., ... Tulchinsky, M. (2012). Cholecystokinin-cholescintigraphy in adults: Consensus recommendations of an interdisciplinary panel. Clinical Nuclear Medicine, 37(1), 63-70. https://doi.org/10.1097/RLU.0b013e31823e26bb

Cholecystokinin-cholescintigraphy in adults : Consensus recommendations of an interdisciplinary panel. / Di Baise, John K.; Richmond, Bryan K.; Ziessman, Harvey A.; Everson, Gregory T.; Fanelli, Robert D.; Maurer, Alan H.; Ouyang, Ann; Shamamian, Peter; Simons, Richard J.; Wall, Laura A.; Weida, Thomas J.; Tulchinsky, Mark.

In: Clinical Nuclear Medicine, Vol. 37, No. 1, 01.2012, p. 63-70.

Research output: Contribution to journalArticle

Di Baise, JK, Richmond, BK, Ziessman, HA, Everson, GT, Fanelli, RD, Maurer, AH, Ouyang, A, Shamamian, P, Simons, RJ, Wall, LA, Weida, TJ & Tulchinsky, M 2012, 'Cholecystokinin-cholescintigraphy in adults: Consensus recommendations of an interdisciplinary panel', Clinical Nuclear Medicine, vol. 37, no. 1, pp. 63-70. https://doi.org/10.1097/RLU.0b013e31823e26bb
Di Baise, John K. ; Richmond, Bryan K. ; Ziessman, Harvey A. ; Everson, Gregory T. ; Fanelli, Robert D. ; Maurer, Alan H. ; Ouyang, Ann ; Shamamian, Peter ; Simons, Richard J. ; Wall, Laura A. ; Weida, Thomas J. ; Tulchinsky, Mark. / Cholecystokinin-cholescintigraphy in adults : Consensus recommendations of an interdisciplinary panel. In: Clinical Nuclear Medicine. 2012 ; Vol. 37, No. 1. pp. 63-70.
@article{c9e895ffdbda44f1ab09bbfd85600a18,
title = "Cholecystokinin-cholescintigraphy in adults: Consensus recommendations of an interdisciplinary panel",
abstract = "Background and aims: Cholecystokinin-cholescintigraphy (CCK-CS) provides a physiologic, noninvasive, and quantitative method for assessing gallbladder contraction and calculation of a gallbladder ejection fraction (GBEF). At present, it is used most commonly to identify patients with suspected functional gallbladder disorder. However, the methodology of CCK infusion and normal values differ markedly among imaging centers. Methods: This document represents the consensus opinion of an interdisciplinary panel that gathered to assess the current optimal method for performing CCK-CS in adults, potential uses and limitations of CCK-CS, and questions that require further investigation. Results: The panel recommended the use of a single, standardized, recently described CCK-CS protocol that involves infusion of 0.02 μg/kg of sincalide over 60 minutes with a normal GBEF defined as ≥38{\%}. The panel emphasized the need for a large, multicenter, prospective clinical trial to establish the utility of CCK-CS in the diagnosis of functional gallbladder disease. Although not without controversy regarding its clinical utility, the primary indication for CCK-CS at present is the well-selected patient with suspected functional gallbladder disorder. Conclusion: Agreement was reached that the adoption of this standardized protocol is critical to improve how CCK-CS is used to direct patient care and will represent an improvement over the diverse methods currently in use by eliminating the current lack of uniformity and adding both reliability and credibility to the results.",
keywords = "Cholecystokinincholescintigraphy, Functional gallbladder disorder, Gallbladder ejection fraction",
author = "{Di Baise}, {John K.} and Richmond, {Bryan K.} and Ziessman, {Harvey A.} and Everson, {Gregory T.} and Fanelli, {Robert D.} and Maurer, {Alan H.} and Ann Ouyang and Peter Shamamian and Simons, {Richard J.} and Wall, {Laura A.} and Weida, {Thomas J.} and Mark Tulchinsky",
year = "2012",
month = "1",
doi = "10.1097/RLU.0b013e31823e26bb",
language = "English (US)",
volume = "37",
pages = "63--70",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Cholecystokinin-cholescintigraphy in adults

T2 - Consensus recommendations of an interdisciplinary panel

AU - Di Baise, John K.

AU - Richmond, Bryan K.

AU - Ziessman, Harvey A.

AU - Everson, Gregory T.

AU - Fanelli, Robert D.

AU - Maurer, Alan H.

AU - Ouyang, Ann

AU - Shamamian, Peter

AU - Simons, Richard J.

AU - Wall, Laura A.

AU - Weida, Thomas J.

AU - Tulchinsky, Mark

PY - 2012/1

Y1 - 2012/1

N2 - Background and aims: Cholecystokinin-cholescintigraphy (CCK-CS) provides a physiologic, noninvasive, and quantitative method for assessing gallbladder contraction and calculation of a gallbladder ejection fraction (GBEF). At present, it is used most commonly to identify patients with suspected functional gallbladder disorder. However, the methodology of CCK infusion and normal values differ markedly among imaging centers. Methods: This document represents the consensus opinion of an interdisciplinary panel that gathered to assess the current optimal method for performing CCK-CS in adults, potential uses and limitations of CCK-CS, and questions that require further investigation. Results: The panel recommended the use of a single, standardized, recently described CCK-CS protocol that involves infusion of 0.02 μg/kg of sincalide over 60 minutes with a normal GBEF defined as ≥38%. The panel emphasized the need for a large, multicenter, prospective clinical trial to establish the utility of CCK-CS in the diagnosis of functional gallbladder disease. Although not without controversy regarding its clinical utility, the primary indication for CCK-CS at present is the well-selected patient with suspected functional gallbladder disorder. Conclusion: Agreement was reached that the adoption of this standardized protocol is critical to improve how CCK-CS is used to direct patient care and will represent an improvement over the diverse methods currently in use by eliminating the current lack of uniformity and adding both reliability and credibility to the results.

AB - Background and aims: Cholecystokinin-cholescintigraphy (CCK-CS) provides a physiologic, noninvasive, and quantitative method for assessing gallbladder contraction and calculation of a gallbladder ejection fraction (GBEF). At present, it is used most commonly to identify patients with suspected functional gallbladder disorder. However, the methodology of CCK infusion and normal values differ markedly among imaging centers. Methods: This document represents the consensus opinion of an interdisciplinary panel that gathered to assess the current optimal method for performing CCK-CS in adults, potential uses and limitations of CCK-CS, and questions that require further investigation. Results: The panel recommended the use of a single, standardized, recently described CCK-CS protocol that involves infusion of 0.02 μg/kg of sincalide over 60 minutes with a normal GBEF defined as ≥38%. The panel emphasized the need for a large, multicenter, prospective clinical trial to establish the utility of CCK-CS in the diagnosis of functional gallbladder disease. Although not without controversy regarding its clinical utility, the primary indication for CCK-CS at present is the well-selected patient with suspected functional gallbladder disorder. Conclusion: Agreement was reached that the adoption of this standardized protocol is critical to improve how CCK-CS is used to direct patient care and will represent an improvement over the diverse methods currently in use by eliminating the current lack of uniformity and adding both reliability and credibility to the results.

KW - Cholecystokinincholescintigraphy

KW - Functional gallbladder disorder

KW - Gallbladder ejection fraction

UR - http://www.scopus.com/inward/record.url?scp=84856448421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856448421&partnerID=8YFLogxK

U2 - 10.1097/RLU.0b013e31823e26bb

DO - 10.1097/RLU.0b013e31823e26bb

M3 - Article

C2 - 22157031

AN - SCOPUS:84856448421

VL - 37

SP - 63

EP - 70

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 1

ER -